Taysha Gene Therapies, Inc. Common Stock (TSHA) is a publicly traded Healthcare sector company. As of November 5, 2026, TSHA trades at $4.07 with a market cap of $1.33B and a P/E ratio of -10.44. TSHA moved -6.58% today. Year to date, TSHA is -10.67%; over the trailing twelve months it is +2.30%. Its 52-week range spans $1.05 to $7.30. Analyst consensus is strong buy with an average price target of $14.00. Rallies surfaces TSHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for TSHA, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $4.07 |
| Market Cap | $1.33B |
| P/E Ratio | -10.44 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.30 |
| 52-Week Low | $1.05 |
| Volume | 1.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.49M |
| Net Income | $-149.63M |
| Gross Margin | 0.00% |
8 analysts cover TSHA: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.00.